Enlicitide
Approved in the US in July 2026; heart-outcomes trial running.
A ring-shaped peptide that does in a daily tablet what injected antibodies do: it blocks so the liver clears more . Made by Merck, also called Lipfendra and MK-0616.
What the evidence shows
Side effects and risks
Who should avoid it: Nothing established beyond the label. Ask the prescriber.
How it works
- Where it acts
- It blocks PCSK9, a protein made by the liver.
- What it changes
- More LDL receptors stay on liver cells, so the liver clears more LDL cholesterol from the blood.
- What people notice
- A large fall in LDL cholesterol in trials, with side effects close to placebo.
How it is taken
One 20 mg tablet a day. Reports at approval describe it as taken in the morning on an empty stomach, 30 minutes before eating.
Getting it in the United States
The legal route for Enlicitide
Get a prescription from a licensed clinician. Fill it at a licensed pharmacy or through the maker's own direct service.
Prescription from any doctor
List price is 315 dollars for 30 days, about half the injectables. Primary care can prescribe. The CEO said insurer coverage would take time to build.
Source: Fierce Pharma, 2026-08
Government discount drug platform
Merck promised a discounted cash price through the federal direct-purchase site as part of its pricing deal with the White House. It follows the main launch. Timing was not given.
Source: Fierce Pharma, 2026-08
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
More contextCase reports, what public figures say, videos and articles and when options run out
Case reports
From journals, regulators and studies of users. One case proves little.
Benefit reportedtrial result in rare group - 303 people - 2026
In adults with inherited high cholesterol (HeFH), LDL fell 59 percent more than placebo at week 24. Diarrhoea and dizziness were more common on the drug. Dropout rates were similar.
Source: touchCARDIO, 2026-07
What experts and influencers say
Paraphrased from the linked sources.
Says a pill could reach patients who never got injectable PCSK9 drugs. Also states it is not yet proven to cut heart attacks or strokes and that statins stay first choice.
Source: UT Southwestern MedBlog, 2026-09
Ann Marie NavarWebsiteRecommends
Money: Lead author of the Merck-sponsored pivotal trial
Photo source: profiles.utsouthwestern.edu
Told investors the launch would start slower than hoped because insurance coverage takes time to build. Still called it a blockbuster opportunity long term.
Source: Fierce Pharma, 2026-08
Money: Chief executive of the maker
Photo source: msd.com
Told the New York Times he was thrilled by the approval.
Christopher CannonWebsiteRecommends
Money: Consults for several drug companies, not Merck
Photo source: vagelos.columbia.edu
Said the lower list price would make a big difference compared with injectable PCSK9 drugs.
David MaronWebsiteRecommends
Photo source: med.stanford.edu
Said that even with pills arriving, he sees strong growth for cholesterol injections given only a few times a year.
Source: Fierce Pharma, 2026-08
Vas NarasimhanSourceWarns against
Money: Heads a company selling a rival injectable
Wrote that Canada has no approval timeline yet. Expects Canadian insurers to wait for heart outcome data before listing it broadly.
Jhoanna HinesWebsiteMixed view
Photo source: benefitsandpensionsmonitor.com
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Merck's Oral PCSK9 Inhibitor Demonstrates Efficacy in Hypercholesterolemia
Don Tracy
News report on Merck's phase 3 CORALreef Lipids trial: oral enlicitide cut LDL cholesterol, including in statin-intolerant adults, with side effects similar to placebo.
Trial news report on the first oral PCSK9 drug
When options run out
Uses people turn to when standard treatment has failed.
Inherited high cholesterol needing several drugs
- Who
- Adults with familial hypercholesterolemia still above target on statins plus other drugs who want to avoid injections.
- Evidence
- A 303-person trial showed large LDL drops. No heart attack or stroke data yet. The outcomes trial reports in 2029.
- Route
- Approved use in the US
People who cannot tolerate statins
- Who
- Patients who tried several statins or doses under a doctor and still had side effects.
- Evidence
- The pivotal trial showed LDL lowering in people on no statin or low doses. About 97 percent of participants took statins, so data here are thin.
- Route
- Approved use in the US
Source: UT Southwestern MedBlog, 2026-09
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Questions people ask
How much does enlicitide lower LDL cholesterol?
LDL fell 56% more than on placebo at 24 weeks, and 59% in people with inherited high cholesterol.
Does enlicitide prevent heart attacks?
That is not yet known. It is being tested in a fully enrolled trial of more than 14,500 people.
What are the side effects of enlicitide?
In one trial, dizziness affected 9% against 4% on placebo and diarrhea 7% against 2%. It is new, and long-term safety results are still to come.
Is enlicitide a pill or an injection?
A pill. It is a ring-shaped peptide taken as a daily tablet that does what injected PCSK9 antibodies do.
Where is Lipfendra approved?
In the US, since July 2026.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Pharmacy Times: FDA approves enlicitide (16 Jul 2026)
- Merck: outcomes trial fully enrolled (30 Mar 2026)
Structure: PubChem